Pyrrolobenzodiazepine-antibody conjugates

1. A method of treating a CD25-expressing lymphoma comprising administering to a patent therapeutically-acceptable amount of a conjugate of formula ConjA:

ConjB:

Conj C:

ConjD:

or ConjE:

where Ab is an antibody which is an antibody that binds to CD25, the antibody comprising: a VH domain comprising a VH CDR1 with the amino acid sequence of SEQ ID NO.3, a VH CDR2 with the amino acid sequence of SEQ ID NO.4, and a VH CDR3 with the amino acid sequence of SEQ ID NO.5; and a VL domain comprising a VL CDR1 with the amino acid sequence of SEQ ID NO.6, a VL CDR2 with the amino acid sequence of SEQ ID NO.7, and a VL CDR3 with the amino acid sequence of SEQ ID NO.8, and wherein the drug loading is from 1 to about 8.

2. The method according to claim 1 , wherein the antibody comprises a VH domain having the sequence according to SEQ ID NO. 1.

3. The method according to claim 1 , wherein the antibody comprises a VL domain having the sequence according to SEQ ID NO. 2.

4. The method according to claim 1 , wherein the antibody is an intact antibody.

5. The method according to claim 1 , wherein the antibody is humanised, deimmunised or resurfaced.

6. The method according to claim 1 , wherein the antibody is a fully human monoclonal IgG1 antibody.

7. The conjugate according to claim 6 , wherein the antibody is IgG1,κ.

8. The method according to claim 1 , wherein the drug loading is 1, 2, 3, or 4.

9. The method according to claim 1 , wherein the conjugate is ConjE.

10. The method according to claim 1 , wherein the lymphoma is a non-Hodgkin Lymphoma.

11. The method according to claim 10 , wherein the non-Hodgkin Lymphoma is selected from diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL) and chronic lymphatic lymphoma (CLL).

12. The method according to claim 1 , wherein a therapeutically effective amount of a chemotherapeutic agent is administered simultaneously or sequentially with the conjugate.